Allegis Investment Advisors LLC Grows Holdings in CVS Health Corp (CVS)

Allegis Investment Advisors LLC raised its stake in CVS Health Corp (NYSE:CVS) by 14.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,817 shares of the pharmacy operator’s stock after buying an additional 2,569 shares during the period. Allegis Investment Advisors LLC’s holdings in CVS Health were worth $1,509,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in CVS. Beach Investment Management LLC. bought a new position in shares of CVS Health during the 2nd quarter worth approximately $2,224,000. Northwestern Mutual Wealth Management Co. raised its stake in shares of CVS Health by 5.9% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 186,632 shares of the pharmacy operator’s stock worth $15,016,000 after acquiring an additional 10,338 shares in the last quarter. Riverhead Capital Management LLC raised its stake in shares of CVS Health by 47.5% during the 2nd quarter. Riverhead Capital Management LLC now owns 97,791 shares of the pharmacy operator’s stock worth $7,868,000 after acquiring an additional 31,510 shares in the last quarter. Oarsman Capital Inc. raised its stake in shares of CVS Health by 7.0% during the 2nd quarter. Oarsman Capital Inc. now owns 39,393 shares of the pharmacy operator’s stock worth $3,170,000 after acquiring an additional 2,582 shares in the last quarter. Finally, Symphony Asset Management LLC bought a new position in shares of CVS Health during the 2nd quarter worth approximately $1,306,000. 83.96% of the stock is owned by institutional investors.

How to Become a New Pot Stock Millionaire

Shares of CVS Health stock opened at $60.86 on Friday. CVS Health Corp has a twelve month low of $60.78 and a twelve month high of $84.00. The stock has a market cap of $62,687.93, a price-to-earnings ratio of 9.41, a P/E/G ratio of 1.01 and a beta of 1.03. The company has a current ratio of 1.02, a quick ratio of 0.52 and a debt-to-equity ratio of 0.59.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Thursday, February 8th. The pharmacy operator reported $1.92 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.88 by $0.04. CVS Health had a net margin of 3.58% and a return on equity of 17.21%. The firm had revenue of $48.39 billion for the quarter, compared to the consensus estimate of $47.54 billion. During the same period in the prior year, the firm posted $1.71 earnings per share. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. analysts anticipate that CVS Health Corp will post 6.37 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, May 3rd. Investors of record on Monday, April 23rd will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 3.29%. The ex-dividend date is Friday, April 20th. CVS Health’s dividend payout ratio (DPR) is presently 30.91%.

Several research analysts recently commented on the stock. Needham & Company LLC set a $98.00 price objective on shares of CVS Health and gave the stock a “buy” rating in a research note on Friday, February 9th. ValuEngine lowered shares of CVS Health from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. Leerink Swann set a $85.00 price target on shares of CVS Health and gave the company a “buy” rating in a research note on Friday, February 9th. Loop Capital set a $73.00 price target on shares of CVS Health and gave the company a “hold” rating in a research note on Monday, December 4th. Finally, Deutsche Bank restated a “hold” rating on shares of CVS Health in a research note on Tuesday, December 5th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $87.03.

In related news, EVP Helena Foulkes sold 19,965 shares of the stock in a transaction on Friday, February 16th. The shares were sold at an average price of $71.04, for a total transaction of $1,418,313.60. Following the sale, the executive vice president now directly owns 65,072 shares of the company’s stock, valued at $4,622,714.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.61% of the company’s stock.

WARNING: This story was published by Ticker Report and is owned by of Ticker Report. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://www.tickerreport.com/banking-finance/3298203/allegis-investment-advisors-llc-grows-holdings-in-cvs-health-corp-cvs.html.

About CVS Health

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

BidaskClub Downgrades Hibbett Sports  to Hold
BidaskClub Downgrades Hibbett Sports to Hold
Innoviva  Rating Lowered to Buy at BidaskClub
Innoviva Rating Lowered to Buy at BidaskClub
$0.60 Earnings Per Share Expected for LHC Group, Inc.  This Quarter
$0.60 Earnings Per Share Expected for LHC Group, Inc. This Quarter
BidaskClub Upgrades National CineMedia  to Hold
BidaskClub Upgrades National CineMedia to Hold
BidaskClub Upgrades PriceSmart  to “Strong-Buy”
BidaskClub Upgrades PriceSmart to “Strong-Buy”
Callaway Golf  Stock Rating Lowered by DA Davidson
Callaway Golf Stock Rating Lowered by DA Davidson


© 2006-2018 Ticker Report. Google+.